Iambic and Takeda Partner on AI-Driven Small Molecule Drug Discovery

Iambic Therapeutics has announced a multi-year collaboration with Takeda to apply its AI-driven discovery platform to small molecule drug design in Takeda’s Oncology and Gastrointestinal and Inflammation therapeutic areas, announced in a press release.

The partnership will give Takeda access to Iambic’s NeuralPLexer model, which predicts protein-ligand complexes to accelerate drug discovery and development. Iambic will receive upfront, research cost, and technology access payments and could earn success-based payments exceeding $1.7 billion, along with royalties on any resulting products.

Iambic’s platform combines AI models with automated synthesis and experimental capabilities, enabling rapid design-make-test-analyze cycles. The collaboration aims to speed up the identification and optimization of small molecule drug candidates in high-priority therapeutic programs.